

TABLE III—TEST INFORMATION RECEIVED FROM 12/1/2022 TO 12/31/2022—Continued

Case No.	Received date	Type of test information	Chemical substance
P-15-0443 .....	12/21/2022	90-Day Inhalation Toxicity Testing (OECD Test Guideline 413).	(G) Rare earth doped zirconium oxide.
P-22-0129 .....	12/14/2022	Water Solubility: Column Elution Method; Shake Flask Method (OECD Test Guideline 105).	(G) Substituted heterocyclic onium compound, salt with heteropolysubstitutedalkyl substitutedtricycloalkane carboxylate (1:1), polymer with 1-alkenyl-4-[(alkylcycloalkyl)oxy]carbomonocycle, 5-ethyloctahydro-4,7-methano-1h-inden-5-yl 2-methyl-2-propenoate, hexahydro-5-oxo-2,6-methanofuro[3,2-b]furan-3-yl 2-methyl-2-propenoate and 4-hydroxyphenyl 2-methyl-2-propenoate.
P-23-0030 .....	12/06/2022	Bacterial Reverse Mutation Test (OECD Test Guideline 471)	(G) Phenol, polyalkylcarbo bis-, polymer with 2-carbomonocyclichaloheteromonocycle, bis[(alkenylcarbomonocyclic)alkyl] ether.

If you are interested in information that is not included in these tables, you may contact EPA’s technical information contact or general information contact as described under **FOR FURTHER INFORMATION CONTACT** to access additional non-CBI information that may be available.

Authority: 15 U.S.C. 2601 *et seq.*

Dated: January 12, 2023.

**Pamela Myrick,**

Director, Project Management and Operations Division, Office of Pollution Prevention and Toxics.

[FR Doc. 2023-00859 Filed 1-17-23; 8:45 am]

BILLING CODE 6560-50-P

**FEDERAL RESERVE SYSTEM**

**Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)).

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than February 17, 2023.

A. *Federal Reserve Bank of Atlanta* (Erien O. Terry, Assistant Vice President) 1000 Peachtree Street NE, Atlanta, Georgia 30309 or electronically to [Applications.Comments@atl.frb.org](mailto:Applications.Comments@atl.frb.org):  
 1. *TIAA FSB Holdings, Inc.*; to become a bank holding company upon the conversion of its subsidiary, TIAA, FBS, both of Jacksonville, Florida, into a national bank.

Board of Governors of the Federal Reserve System.

**Michele Taylor Fennell,**

Deputy Associate Secretary of the Board.

[FR Doc. 2023-00857 Filed 1-17-23; 8:45 am]

BILLING CODE P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Agency for Healthcare Research and Quality**

**Agency Information Collection Activities: Proposed Collection; Comment Request**

**AGENCY:** Agency for Healthcare Research and Quality, HHS.

**ACTION:** Notice.

**SUMMARY:** This notice announces the intention of the Agency for Healthcare Research and Quality (AHRQ) to request that the Office of Management and Budget (OMB) approve the proposed information collection project “Supporting and Evaluating the Dissemination and Implementation of PCOR to Improve Non-Surgical Treatment of Urinary Incontinence Among Women in Primary Care.” This proposed information collection was previously published in the **Federal Register** on October 28, 2022 and allowed 60 days for public comment. AHRQ received no substantive comments. The purpose of this notice is to allow an additional 30 days for public comment.

**DATES:** Comments on this notice must be received by February 17, 2023.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.

**FEDERAL ELECTION COMMISSION**

**Sunshine Act Meetings**

**FEDERAL REGISTER CITATION NOTICE OF PREVIOUS ANNOUNCEMENT:** 88 FR 863.

**PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING:** Tuesday, January 10, 2023 at 10:00 a.m. and its continuation at the conclusion of the open meeting on January 12, 2023.

**CHANGES IN THE MEETING:** The meeting began at 10:30 a.m. on January 10, 2023.

The meeting also discussed:

Matters relating to internal personnel decisions, or internal rules and practices.

\* \* \* \* \*

**FOR MORE INFORMATION CONTACT:** Judith Ingram, Press Officer, Telephone: (202) 694-1220.

(Authority: Government in the Sunshine Act, 5 U.S.C. 552b)

**Vicktoria J. Allen,**

Acting Deputy Secretary of the Commission.

[FR Doc. 2023-00905 Filed 1-13-23; 11:15 am]

BILLING CODE 6715-01-P